Patterson-UTI Energy Inc.

PTEN | NASDAQ

Price Alert Chart Builder DCF Calculator

$11.14

-$0.28 (-2.45%)

At close: Sep 22, 2026, 4:00 PM ET

$11.25

+$0.11 (+0.99%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.45%

(1D)

Rating

Updated: Aug 13, 2026

26.6

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $4.23B

1D Range

11.12 11.51

52W Range

5.10 13.39

Valuation (TTM)

PE -47.58

PB 1.40

EV/EBITDA 5.40

Valuation (NTM)

Forward PE 41.76

Forward PEG 0.02

Price Target $13.43

Cash Flow

FCF Yield 4.1%

SBC Adj. FCF Yield 3.4%

SBC Impact -17.1%

Margins

Gross Margin 14.2%

Operating Margin -1.1%

FCF Margin 3.8%

Growth (CAGR)

Revenue 3Y | 5Y 15.1% | 37.2%

Dil EPS 3Y | 5Y -30.7% | -8.3%

FCF 3Y | 5Y -22.6% | 50.2%

Returns

ROA -1.7%

ROE -2.8%

ROIC -1.2%

Financial Health

Net Cash

$203.17M

Current Ratio 1.75

Interest Coverage -0.73

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Patterson-UTI Energy, Inc. (PTEN) is a key provider of onshore contract drilling services for oil and natural gas exploration and production companies. Its operations span across the United States and...

Sector Energy

Industry Oil & Gas Drilling

Employees 7,900

IPO Date Nov 1, 1993

Website www.patenergy.com

Fiscal Year January - December

Full Company Profile

Latest News

27 days ago · zacks.com

Why Is Patterson-UTI (PTEN) Up 24.5% Since Last Earnings Report?

Patterson-UTI (PTEN) reported earnings 30 days ago. What's next for the stock?

27 days ago · gurufocus.com

Patterson-UTI Energy Inc (PTEN) Shares Surge 4.4% -- What GF Score of 60 Tells Investors

On August 27, 2026, Patterson-UTI Energy Inc (PTEN) shares rose 4.4% to $12.26, continuing a strong upward trend over the past month. The stock has seen signifi

1 month ago · zacks.com

Oil Above $80: 2 Energy Stocks You Don't Want to Miss

Oil above $80 is boosting the outlook for Patterson-UTI and Cactus as Middle East tensions support crude prices and upstream activity.

2 months ago · zacks.com

Does Patterson-UTI (PTEN) Have the Potential to Rally 37.91% as Wall Street Analysts Expect?

The mean of analysts' price targets for Patterson-UTI (PTEN) points to a 37.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

2 months ago · zacks.com

Should Value Investors Buy PattersonUTI Energy (PTEN) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

2 months ago · zacks.com

Are Oils-Energy Stocks Lagging PattersonUTI Energy (PTEN) This Year?

Here is how Patterson-UTI (PTEN) and SunCoke Energy (SXC) have performed compared to their sector so far this year.

2 months ago · zacks.com

Patterson-UTI (PTEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Patterson-UTI (PTEN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

2 months ago · zacks.com

PTEN Jumps 20% in a Month as Rig Pricing and Demand Strengthen

Patterson-UTI's longer contracts, higher dayrates and packed frac calendar point to better cash flow, but losses and commodity exposure remain.

2 months ago · prnewswire.com

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.